Achievable logoAchievable logo
USMLE/1
Sign in
Sign up
Purchase
Textbook
Support
How it works
Resources
Exam catalog
Mountain with a flag at the peak
Textbook
Introduction
1. Anatomy
2. Microbiology
3. Physiology
4. Pathology
5. Pharmacology
5.1 Pharmacokinetics
5.2 Pharmacodynamics
5.3 Receptors, agonists and antagonists
5.4 Types of drug receptors
5.5 Anti-neoplastic drugs
5.6 Adverse effects of chemotherapeutic drugs
5.7 Newer chemotherapeutic drugs
5.8 Important drugs of the cardiovascular system
5.8.1 Drugs affecting coagulation
5.8.2 Drugs used in the treatment of hypertension
5.8.3 Anti-anginal drugs
5.8.4 Antiarrhythmics
5.8.5 Lipid lowering agents
5.8.6 Miscellaneous
5.9 Antimicrobials
5.10 Drugs acting on the renal system
5.11 Drugs acting on the respiratory system
5.12 Drugs acting on the gastrointestinal system
5.13 Antidiabetics and insulin
5.14 Miscellaneous
5.15 Additional information
6. Immunology
7. Biochemistry
8. Cell and molecular biology
9. Biostatistics and epidemiology
10. Genetics
11. Behavioral science
Wrapping up
Achievable logoAchievable logo
5.8.6 Miscellaneous
Achievable USMLE/1
5. Pharmacology
5.8. Important drugs of the cardiovascular system

Miscellaneous

3 min read
Font
Discuss
Share
Feedback

Miscellaneous drugs of the cardiovascular system

Dopamine: Dopamine is the precursor to norepinephrine.

  • At low doses (0.5 to 3 microgram/kg/min), it stimulates D1 and D2 receptors, causing vasodilation and increasing circulation in the renal, coronary, mesenteric, and cerebral vasculature. It promotes natriuresis.
  • At intermediate doses (3 to 10 microgram/kg/min), dopamine binds to and activates beta 1 receptors, resulting in positive inotropy, chronotropy, and a mild increase in systemic vascular resistance.
  • At doses higher than 10 microgram/kg/min, vasoconstriction from alpha 1 stimulation is predominant.

It is used in the treatment of shock, symptomatic bradycardia, and heart failure.

Dobutamine: Dobutamine activates chiefly beta 1 and beta 2 receptors.

  • Effects include positive inotropy and chronotropy.
  • Vasoconstriction occurs only at high doses (> 20 microgram/kg/min).

It is used in the treatment of decompensated heart failure, cardiogenic shock, and symptomatic bradycardia. It is also used diagnostically in dobutamine stress echo or imaging because it increases myocardial oxygen consumption.

Norepinephrine: Norepinephrine is a potent alpha 1 receptor agonist with modest beta agonist activity. This makes it a powerful vasoconstrictor with less potent direct inotropic properties.

  • It primarily increases systolic, diastolic, and pulse pressure.
  • It has a minimal net impact on cardiac output.
  • It has only a mild positive chronotropic effect.
  • Prolonged infusion can cause myocyte apoptosis.

It is used in the treatment of shock.

Epinephrine: Epinephrine is a potent activator of alpha 1, beta 1, and beta 2 receptors.

  • High doses may cause myocardial necrosis and apoptosis.

It is used in the treatment of shock, cardiac arrest, anaphylaxis, and symptomatic bradycardia. Adverse effects include ventricular arrhythmias, sudden cardiac death, ICH, and severe hypertension.

Isoproterenol: Isoproterenol is a potent non-selective beta agonist.

  • It increases chronotropy and inotropy.
  • It causes systemic and pulmonary vasodilation.

It is used in the treatment of bradyarrhythmias, torsade des pointes, and Brugada syndrome.

Phenylephrine: Phenylephrine is a potent activator of alpha 1 receptors.

  • It causes intense vasoconstriction, elevated blood pressure, and reflex bradycardia.

It is used in the treatment of severe hypotension, especially in the setting of aortic stenosis and HOCM.

Amrinone/Milrinone: Amrinone and milrinone inhibit the enzyme phosphodiesterase.

  • This increases intracellular cAMP levels and increases myocardial contractility (positive inotropy).
  • They decrease preload and afterload.
  • They improve diastolic relaxation (positive lusitropic effect).

They are used in the treatment of low cardiac output states such as decompensated heart failure. Milrinone is more commonly used because amrinone is associated with thrombocytopenia and hepatotoxicity.

Levosimendan: Levosimendan is a newer inotropic drug.

  • Its mechanism includes calcium sensitization of contractile proteins such as troponin-C, which improves contractility.
  • It also opens ATP dependent K+ channels, causing vasodilation.

It is used in the treatment of acute and chronic heart failure.

All rights reserved ©2016 - 2026 Achievable, Inc.